Trial Profile
An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma Initially Treated with an Injection of Proteasome Inhibitor-Based Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Sep 2022
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary) ; Bortezomib; Carfilzomib
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Takeda
- 04 Jun 2021 Status changed from active, no longer recruiting to completed.
- 01 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 19 Mar 2019 Planned primary completion date changed from 28 Feb 2020 to 31 Aug 2020.